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Background and Objective: Acute bacterial skin and skin structure infections have been 
defined by Food and Drug Administration (FDA) in 2013 to define a subset of complicated skin 
and skin structure infections commonly treated with parenteral antibiotic therapy. Inpatient 
treatment of ABSSSIs involves a significant economic burden on the health-care system. This 
study aimed to evaluate the economic impact on National Health System associated with the 
management of non-severe ABSSSIs treated in hospitals with innovative long-acting 
dalbavancin compared to standard antibiotic therapy in Italy, Spain and Austria. 
Methods: A Budget Impact Analysis was developed to evaluate the direct costs associated 
with the management of ABSSSI from the national public health system perspective. The 
model considered the possibility to early discharge patients directly from the Emergency 
Department (ED), after one night in the hospital or after 2 or 3 night in the hospital. A scenario 
with Standard of Care was compared with dalbavancin scenario, where patients had the 
possibility of being early discharged. The epidemiological and cost parameters were 
extrapolated from national administrative databases and from a systematic literature review 
for each Country. The analysis was conducted in a 3-year time horizon. A one-way 
deterministic sensitivity analysis was conducted to examine the robustness of the results. 
Results: The model estimated an average annual number of patients with non-severe ABSSSI 
in Italy, Spain and Austria equal to 5,396, 7,884 and 1,788 respectively. A total annual 
expenditure of about € 9.9 million, € 13.5 million and € 3.4 million was estimated for treating 
the full set of ABSSSI patients in Italy, Spain and Austria respectively. Dalbavancin reduced the 
in-hospital length of stay in each Country. In the first year of its introduction, Dalbavancin 
significantly reduced the total economic burden in Italy and Spain (-€ 352,252 and -€ 233,991) 
while it increased the total economic burden in Austria (€ 80,769, 0.7% of the total 
expenditure for these patients); in the third year of its introduction, Dalbavancin reduced the 
total economic burden in each Country (-€ 1,1 million, -€ 810,650, -€ 70,269 respectively). 
Conclusions: The introduction of dalbavancin in a new patients pathway to treat non-severe 
aBSSSI, could generate a significant reduction of hospitalized patients and the overall patient's 





Key Points:  
- Dalbavancin reduces the in-hospital length of stay in each Country.  
- The introduction of dalbavancin in a new patients pathway to treat non-severe aBSSSI 







Skin and skin structure infection (SSSI) represents one of the most frequent infections 
treated in a hospital setting [1, 2]. Skin and soft tissue infection are generally defined as 
complicated (cSSTI) when they require inpatient management or surgical procedures or they 
are associated with comorbidities, such as diabetes or systemic immunosuppression, that can 
complicate a patient’s response to treatment [1]. 
In 2013, the US Food and Drug Administration (FDA) introduced the term “acute 
bacterial skin and skin structure infections” (ABSSSIs) to define a subset of complicated SSTIs 
commonly treated with parenteral antibiotic therapy [3]. Based on the FDA guidelines, 
ABSSSIs include cellulitis, erysipelas, wound infections, and major cutaneous abscesses with 
a minimum lesion surface area of 75 cm2 [3]. 
Many pre-existing chronic conditions, such as obesity, lymphedema, venous 
insufficiency, and prior trauma to the area, have been associated with an increased risk of 
developing ABSSSIs [4, 5]. Common bacterial pathogens causing ABSSSI are Streptococcus 
pyogenes and Staphylococcus aureus, including methicillin-resistant strains (MRSA) [3]. Less 
commonly identified bacteria include other Streptococcus species, Enterococcus faecalis, and 
gram-negative bacteria [3]. Staphylococcus aureus is the most common cause of ABSSSIs in all 
regions of North America, Latin America and Europe [6]. 
The European Union (EU) and European Economic Area (EEA) population-weighted 




nevertheless, MRSA remains an important pathogen in the EU/EEA since the levels of MRSA 
are still high in several countries [7]. 
The highest percentages of invasive isolates with methicillin resistance (MRSA) have 
been observed in Spain, Portugal, Italy, Greece, Bulgaria, Croatia and Slovakia, with ranges 
from 25% to 50%; followed by France, Ireland, the Czech Republic, Poland, Hungary and 
Romania, with ranges from 10% to 25%; and the UK, Belgium, Germany, Austria, Slovenia, 
Lithuania and Latvia, with ranges from 5% to 10% [7]. 
The most serious ABSSSIs that require hospitalization for parenteral antibiotic therapy 
are diagnosed on the basis of the virulence and resistance patterns of the causative pathogens 
and host factors, which can potentially increase the severity of the infection [1, 8-11]. If 
misdiagnosed or not managed appropriately, these acute infections can lead to complications 
that may have a devastating impact on the quality of life of patients, and they may increase 
the risk of mortality [12]. According to recent guidelines [4], ABSSSIs are classified based on 
clinical severity as mild, moderate or severe infections. Severe ABSSSIs are those that do not 
respond to empirical antibiotic treatment and/or surgical drainage and are generally 
associated with signs of systemic infection (fever> 38 °C, elevated white blood cells). ABSSSIs 
in immunocompromised patients are also considered severe. Mild skin infections are usually 
resolved with incision and drainage, while moderate ABSSSIs could benefit from incision and 
drainage but commonly require a short course of antibiotic therapy, thus often resulting in a 
short duration of hospitalization. For patients with severe infections, clinical reassessment is 
usually performed 72 hours after hospitalization (discharge on day 4 or prolonged observation 
until day 8), while the treatment duration is indicated to be 7–14 days (discharge on day 8 or 
prolonged observation, corresponding to hospitalization for more than 8 days). Patients with 
moderate (non-severe) infections are generally hospitalized for ≤ 2-3 days. 
The 2014 Practice Guidelines for the Diagnosis and Management of Skin and Soft 
Tissue Infections released by the Infectious Diseases Society of America (IDSA) identified two 
additional categories of ABSSSIs: non-purulent (cellulitis and erysipelas) and purulent 
(abscesses, carbuncles, and furuncles). The guidelines also recommended an algorithm for 
the management of each type of infection based on differences in microbiology and severity 
of illness [4]. These infections are more likely to be caused by Staphylococcus aureus, 




of the positive cultures from ABSSSIs from accident and emergency departments (A&EDs) 
[13]. 
Based on this evidence, the US FDA is looking at early clinical response, defined as the 
cessation of spread of the primary lesion and resolution of fever within 48–72 hours after 
enrolment, as the main endpoint for the approval of new antibiotic therapies indicated for 
the treatment of ABSSSIs. New approved agents have been designed to decrease the rate of 
hospitalization and the length of stay (LoS) (with both intravenous and oral formulations 
available for ease of transition at discharge), while improving safety/tolerability and 
increasing the spectrum of activity to act against increasingly resistant pathogens [14]. There 
may be a potential benefit of cost-prevention by decreasing the LoS and reducing the need 
for hospital admission  through the administration of long-acting lipoglycopeptides in either 
inpatient or outpatient settings, although supporting data are limited [14]. 
Dalbavancin is a semisynthetic lipoglycopeptide that is active against several 
multidrug-resistant gram-positive bacteria, including MRSA [15]. The main advantage of 
dalbavancin is its long half-life (up to 14 days), which allows once-weekly administration and 
an early hospital discharge [15]. In the DISCOVER-1 and DISCOVER-2 randomized clinical trials 
(RCTs), dalbavancin was not inferior to twice-daily intravenous vancomycin followed by oral 
linezolid for the treatment of ABSSSIs. The most common adverse events (AEs) reported were 
mild gastrointestinal side effects that rarely led to the discontinuation of the treatment [16]. 
A previous study aimed to evaluate the direct costs associated with the management 
of severe ABSSSI patients from a national health-care provider’s perspective in Italy, Romania, 
and Spain. The administration of dalbavancin resulted in a mean reduction in hospital stay of 
3.3 days per ABSSSI patient, with no significant incremental costs from a National Health 
System perspective [17]. This paper concluded that the use of dalbavancin could allow early 
discharge ABSSSI management, potentially significantly reducing patients’ exposure to 
additional risks associated with prolonged hospitalization, with no incremental cost for the 
National healthcare providers. What happens to the non-severe ABSSSIs? Could they have 
advantages due to the long-acting bactericidal activity of and unique dosing schedule for 
dalbavancin? 
The objective of this research is to evaluate the economic impact on National Health 




according to IDSA definition) treated in hospitals with innovative long-acting dalbavancin 
respect to standard antibiotic therapy in Italy, Spain and Austria. 
 
2. Methods 
A budget impact analysis (BIA) was developed to estimate the direct costs associated 
with the management of ABSSSIs from the public National Health System perspective. The 
methodology followed the guidelines recommended by the International Society of 
Pharmacoeconomics and Outcome Research (ISPOR) Principles of Good Practice [21]. Similar 
to a previously published paper [17], literature data and clinical experts’ opinions were used 
as inputs in the model when primary data were not available [21]. 
 A decision-analytic model was developed on the basis of the current clinical practices 
in three European countries with the aim of simulating the hospital management of non-
severe ABSSSI patients receiving empiric treatment with antibiotics (Figure 1). 
The analysis was conducted over a 3-year time period considering the standard 
guidelines suggested for a BIA [21]. 
The choice of the countries was based on the percentages of invasive isolates with 
methicillin resistance (MRSA) registered in each country. We considered two countries with 
high levels of MRSA (Italy and Spain) and one country with a lower percentage (Austria) [7].  
Most of the 28 countries in the European Union have a publicly funded national system 
that provides universal access to healthcare. However, the relevance of MRSA widely varies 
around the EU28 (mean value of 16.9% in 2017) [7]. Based on the relevance of this 
epidemiological impact, the simulation included the two EU countries with the higher 
percentage of MRSA (Italy and Spain, 25-50% in 2017) and the country with the lowest level 
of MRSA (Austria, 5 – 10%)  [7]. 
 
2.1 Eligible population 
Eligible patients were identified using the national administrative databases of each 
country (Appendix A). The algorithm included all acute inpatient admissions. The data 




Spain, January 1st, 2006, to December 31st, 2014; and Austria, January 1st, 2008, to 
December 31st, 2014. 
 
2.2 Intervention comparison and model structure 
The decision tree model reported in Figure 1 shows that all ABSSSI patients can 
undergo the following: 
a) early discharge (directly from the emergency department - ED), 
b) discharge after one night in the hospital, 
c) discharge after 2 or 3 night in the hospital (first probabilistic node). 
The patients initially receive empirical antibiotic treatment to cover gram-positive 
infections and remain in the hospital for an observational period of a few hours (a), for 24 
hours (b) or for 2 or 3 nights (c). The model considers that the patients could receive either a 
prescription for oral antibiotics before discharge (current intervention or standard of care - 
SoC) or the administration of dalbavancin (new intervention). The choice of antibiotic 
combination therapy was based on the IDSA guidelines for the treatment of non-severe 
ABSSIs [18]. 
After receiving antibiotic therapy and discharge, the patients could have a successful 
clinical response (no additional hospitalization due to aBSSSI) or a poor clinical response 
(leading to a new admission to the hospital - second probabilistic node). Patients with a poor 
clinical response could present clinical worsening or a severe clinical worsening (third 
probabilistic node). The transition probabilities change according to the treatment options 
(SoC or dalbavancin) administered on day 0. 
 
Figure 1: Decision tree 
ABSSSIs: Acute Bacterial Skin and Skin Structure Infections 
Discharged: early discharge (directly from the emergency department - ED) 
Hospitalized 0-1: hospitalization for 0-1 day (1 night) 
Hospitalized 2-3: hospitalization for 2-3 days (2-3 nights) 
Successful clinical response: no additional hospitalization due to aBSSSI 
Poor clinical response: leading to a new admission to the hospital 
Non severe clinical worsening: re-hospitalization with a length of stay (LoS) < 4 days 









2.3 Non-monetary inputs to the model 
The input values of the probabilistic nodes are reported in Table 1. 
For the SoC scenario, the proportion of non-severe ABSSSI patients in the two starting 
groups (0-1 days or 2-3 days in hospital) was obtained from the real-world databases of each 
country (details are provided in the appendix). 
In the dalbavancin administration scenario, the starting distribution could change 
accordingly to the following: 1) the number of patients treated with dalbavancin, 2) the 
percentage of patients who could be discharged earlier than SoC-treated patients and 3) the 
reduced rate of re-hospitalization. 
Regarding the number of patients treated with dalbavancin, the model assumes that 
an increasing number of patients during the 3-year follow-up will be treated with the new 
antibiotic depending on the severity of the disease and the observational period required in 
the SoC scenario (Table 1). 
The ability to reduce the number of hospitalization days attributed to the 
administration of dalbavancin was based on experts’ opinions and was supported by their 
current clinical practices. Replacing the current SoC (empirical antibiotic treatment) with the 
early administration of dalbavancin could potentially lead to a significant reduction in the 
mean hospitalization time associated with non-severe ABSSSI: 
- (a) Day 0: Dalbavancin administered in the ED could reduce the number of patients 
who remain in the hospital for 1 or 2-3 nights (assumed equal to 90% for each 
treated patient in the base-case scenario – Table 1); 
- (b) Day 1: Dalbavancin administered after one day of observation could reduce the 
number of patients who remain in the hospital for a second or third day); 
- (c) Day 2-3: Some patients remain in the hospital even if they were previously 
treated with dalbavancin on days 0 or 1. The base case analysis assumes that 
patients who stay in the hospital for 2-3 days in the SoC scenario, when treated 




the rest of the treated patients are discharged after one day (Table 1). This 
percentage increases in years two and three (30 and 50%, respectively), assuming 
increasing confidence in the new drug by physicians. 
The model conservatively assumes that the risk of clinical worsening remains the same 





Table 1: Transition probabilities: SoC (real-world data) vs. dalbavancin (expert opinion) 
Patients with ABSSSIs in the SoC scenario (first probabilistic node) ITALY SPAIN AUSTRIA References 
Discharge   0.0% 0.0% 0.0% Data from 
administrative 
databases 
Hosp. 0-1   41.0% 55.0% 21.2% 
Hosp 2-3   59.0% 45.0% 78.8% 
Clinical response probability (second probabilistic node)     





Success   98.5% 98.5% 98.5% 
Poor Response   1.5% 1.5% 1.5% 
Hosp 0-1      
Success   98.5% 98.5% 99.0% 
Poor Response   1.5% 1.5% 1.0% 
Hosp 2-3      
Success   99.1% 99.1% 99.4% 
Poor Response   0.9% 0.9% 0.6% 
Clinical worsening probability (third probabilistic node)     




Non-severe clinical worsening   94.8% 94.8% 94.8% 
Severe clinical worsening   5.2% 5.2% 5.2% 
Hosp 0-1      
Non-severe clinical worsening   94.8% 94.8% 94.8% 
Severe clinical worsening   5.2% 5.2% 5.2% 
Hosp 2-3      
Non-severe clinical worsening   90.5% 90.5% 90.5% 
Severe clinical worsening   9.5% 9.5% 9.5% 
Dalbavancin administration Year 1 Year 2 Year 3 References 
Dalbavancin administration Hosp. 0-1 15.0% 25.0% 40.0% Expert opinion 
Efficacy in patients with Hosp 0-1  90.0% 90.0% 90.0%  
Dalbavancin administration Hosp. 2-3 20.0% 35.0% 50.0%  
Efficacy in patients with Hosp 2-3  90.0% 90.0% 90.0%  
Success from Hosp 2-3 to discharge  15.0% 30.0% 50.0% 
Patients with ABSSSIs in the dalbavancin scenario - ITALY      
Discharge  7.1% 14.8% 28.0%  
Hosp. 0-1  44.5% 44.8% 39.5% Calculation 
Hosp 2-3  48.4% 40.4% 32.5%  
Patients with ABSSSIs in the dalbavancin scenario - SPAIN      
Discharge  8.6% 16.6% 29.9%  
Hosp. 0-1  54.5% 52.6% 45.3% Calculation 
Hosp 2-3  36.9% 30.8% 24.7%  
Patients with ABSSSIs in the dalbavancin scenario - AUSTRIA      
Discharge  5.0% 12.2% 25.4%  
Hosp. 0-1  30.4% 33.8% 31.3% Calculation 
Hosp 2-3  64.6% 54.0% 43.4%  
SoC: Standard of Care 
ABSSSIs: Acute Bacterial Skin and Skin Structure Infections 
Hosp 0-1: hospitalization for 0-1 day (1 night) 





2.4 Cost inputs in the model 
Tariffs and direct costs associated with each hospitalization type and length of stay 
were used as inputs to inform the model (Table 2). For Italy, the costs were derived from the 
Italian National Tariffs associated with each specific diagnosis-related group (DRG), as 
reported in the epidemiological and risk analysis (Appendix). For patients with clinical 
worsening, the estimated costs of re-hospitalization were considered, assuming a LoS < 4 days 
for non-severe worsening and a LoS ≥ 4 days for severe worsening. 
For Spain, the hospitalization costs were derived from the official Spanish database 
(http://pestadistico.inteligenciadegestion.msssi.es/publicosns), which includes tariffs for 
minor patients (LoS = 0-1 days) or moderate patients (LoS = 2-3 days). Due to a lack of data, 
the average hospitalization costs due to clinical worsening were increased by the same 
percentages used in the Italian scenario. 
For Austria, the required data were not available publicly. Moreover, ABSSSIs are not 
clearly identifiable in the DRG system but are mostly a component of a wider DRG category. 
Therefore, a data request was made to cross-reference DRG and ICD information on different 
LoSs (for details see appendix). As only part of the hospital costs are paid by the DRG tariff, 
the latter does not reflect the economic costs of the treatment [19]. To adjust for this, we 
used information on total inpatient costs from the Austrian hospital accounting system, also 
requested from the MoH. However, the perspective of this study is that of the national health 
system; therefore, we deducted private payments for hospital inpatient stays, as these 
payments mostly cover additional amenities that incur costs not covered by the public 
system. The remaining inpatient costs were divided by the total DRG points to obtain 
cost/DRG, which can be applied to the DRG points of relevant stays. 
In the model, the dalbavancin drug cost was estimated considering that patients are 





Table 2: Cost inputs for each country included in the analysis (year 2018) 
Cost parameters ITALY SPAIN AUSTRIA References 





Admitted to ED with clinical worsening € 1,089.1 € 1,238.0 € 1,461.7 
Admitted to ED with severe clinical worsening € 3,163.0 € 3,595.5 € 3,806.9 
Hosp 0-1 € 490.0 € 557.0 € 1,228.0 
Hosp 0-1 with clinical worsening € 1,089.1 € 1,238.0 € 2,535.3 
Hosp 0-1 with severe clinical worsening € 3,163.0 € 3,595.5 € 4,880.6 
Hosp 2-3 € 2,735.3 € 3,073.8 € 2,085.4 
Hosp 2-3 with clinical worsening € 2,226.1 € 2,501.6 € 3,392.7 
Hosp 2-3 with severe clinical worsening € 2,748.7 € 3,088.9 € 5,737.9 
Dalbavancin  € 1,161.0 € 1,290.0 € 1,200.0* [17] 
* Estimated cost. 
ED: Emergency Department 
Hosp 0-1: hospitalization for 0-1 day (1 night) 
Hosp 2-3: hospitalization for 2-3 days (2-3 nights) 
 
 
2.5 Sensitivity analysis 
One-way deterministic sensitivity analysis (DSA) was performed to evaluate the 
impact of uncertainty of input parameters on the results. Such analysis consists of changing 
one input parameter at a time, according to the minimum and maximum values found in the 
literature or assumed by the authors. In this specific case, the minimum and maximum values 
were defined assuming ±10% variability for each parameter. 
3. RESULTS 
Figure 2 shows the average annual number of patients affected by non-severe ABSSSIs 
in each country included in the analysis. The model identified 5,396 non-severe ABSSSIs 
patients in Italy; 41% (2,212) of these patients were hospitalized with a LoS of 0-1 days, while 
59% (3,183) were hospitalized with a LoS of 2-3 days. In Spain, 7,884 non-severe ABSSSIs 
patients were identified; 55% (4,337) of these patients were hospitalized with a LoS  of 0-1 




ABSSSIs patients were identified; 21.2% (378) had a LoS of 0-1 days and 78.8% were 
hospitalized with a LoS of 2-3 days. 
Figure 2: Average annual number of patients affected by non-severe ABSSSIs hospitalized in 
Italy (2006–2014), Spain (2006–2014), and Austria (2008–2014). 
ABSSSIs: Acute Bacterial Skin and Skin Structure Infections 
LoS: Length of stay 
0-1 day: hospitalization for 0-1 day (1 night) 
2-3 days: hospitalization for 2-3 days (2-3 nights) 
 
 
After the first year of observation, dalbavancin treatment reduced the in-hospital LoS 
by approximately 230 days, 207.4 days and 261.8 days per 1,000 hospitalised ABSSSI patients 
in Italy, Spain and Austria, respectively. By the third year of observation, these reductions 
increased to -677.1, -601.8 and -782.6 days per 1,000 hospitalized ABSSSI patients in Italy, 
Spain and Austria, respectively (Figure 2). 
From an economic perspective, the model estimated a total annual expenditure of € 
9.9 million, € 13.5 million and € 3.4 million for the treatment of all hospitalized non-severe 
ABSSSI patients in Italy, Spain and Austria, respectively (Table 4). In Italy, the early use of 
dalbavancin decreased the total annual treatment costs by € 352,252 in year 1 and € 1.1 
million in year 3. Similar annual savings, ranging from € 233.991 (year 1) to € 810,650 (year 
3), were realized in Spain. In Austria, dalbavancin appeared to be associated with a moderate 
total annual increase of € 80.769 in the first year of observation, but this was offset by an 
estimated cost savings of € 70.269 in the last year of the simulation (Table 4). 
Figure 3: In-hospital length of stay (days per 1,000 hospitalized ABSSSI patients) in the SoC 
and dalbavancin scenarios 






Table 4: Annual costs for the SoC and dalbavancin scenarios and budget impact results 
 
SoC  Dalbavancin  Difference (dalbavancin - SoC) 
  Italy Spain Austria  Italy Spain Austria  Italy Spain Austria 
  Year 1 
Discharged € 0.0 € 0.0 € 0.0  € 453,544.4 € 893,009.0 € 109,152.2  € 453,544.4 € 893,009.0 € 109,152.2 
Hosp 0-1 € 1,124,354.1 € 2,505,808.5 € 474,578.7  € 1,824,126.6 € 3,265,132.4 € 946,686.8  € 699,772.5 € 759,323.9 € 472,108.1 
Hosp 2-3 € 8,774,934.2 € 10,988,014.6 € 2,968,488.6  € 7,269,365.6 € 9,101,691.1 € 2,467,997.3  -€ 1,505,568.6 -€ 1,886,323.5 -€ 500,491.4 
Total € 9,899,288.2 € 13,493,823.1 € 3,443,067.3  € 9,547,036.6 € 13,259,832.5 € 3,523,836.2  -€ 352,251.6 -€ 233,990.6 € 80,768.9 
  Year 2 
Discharged € 0.0 € 0.0 € 0.0  € 941,734.6 € 1,718,501.5 € 267,362.5  € 941,734.6 € 1,718,501.5 € 267,362.5 
Hosp 0-1 € 1,124,354.1 € 2,505,808.5 € 474,578.7  € 2,107,310.3 € 3,542,772.7 € 1,142,059.0  € 982,956.2 € 1,036,964.1 € 667,480.3 
Hosp 2-3 € 8,774,934.2 € 10,988,014.6 € 2,968,488.6  € 6,140,189.1 € 7,686,948.5 € 2,092,628.7  -€ 2,634,745.0 -€ 3,301,066.1 -€ 875,859.9 
Total € 9,899,288.2 € 13,493,823.1 € 3,443,067.3  € 9,189,234.1 € 12,948,222.7 € 3,502,050.2  -€ 710,054.2 -€ 545,600.4 € 58,982.9 
  Year 3 
Discharged € 0.0 € 0.0 € 0.0  € 1,783,827.0 € 3,092,740.1 € 555,166.5  € 1,783,827.0 € 3,092,740.1 € 555,166.5 
Hosp 0-1 € 1,124,354.1 € 2,505,808.5 € 474,578.7  € 2,017,961.2 € 3,318,227.4 € 1,100,372.1  € 893,607.1 € 812,418.8 € 625,793.4 
Hosp 2-3 € 8,774,934.2 € 10,988,014.6 € 2,968,488.6  € 5,011,012.7 € 6,272,205.9 € 1,717,260.2  -€ 3,763,921.5 -€ 4,715,808.7 -€ 1,251,228.5 
Total € 9,899,288.2 € 13,493,823.1 € 3,443,067.3  € 8,812,800.8 € 12,683,173.3 € 3,372,798.8  -€ 1,086,487.5 -€ 810,649.8 -€ 70,268.5 




     
Total € 29,697,864.7 € 40,481,469.4 € 10,329,202.0  € 27,549,071.5 € 38,891,228.6 € 10,398,685.2  -€ 2,148,793.3 -€ 1,590,240.8 € 69,483.2 
SoC: Standard of Care 
Hosp 0-1: hospitalization for 0-1 day (1 night) 





Figures 4a, 4b e 4c, shows the results of the deterministic sensitivity analyses conducted for 
each country; the variable that mainly affected the cumulative budget impact of each country was 
the second probabilistic node for patients who stay in the hospital for 2-3 days, both for SoC and 
dalbavancin scenario. In all the simulated scenario, dalbavancin represent a cost-saving option for 
Italy and Spain with a cumulative cost reduction between € 4.3 - € 0.7 and € 4.3 - € 0.3 respectively 
(Figure 4A and 4C). A similar effect was reported for Austria, where the variability over the main 
considered parameters estimates an incremental cost between - € 0.4 million if we increase the 
probability of successful clinical response of dalbavancin and +€ 1.1 million if we decrease the 
Dalbavancin effect in the second node (Figura 4 C). 
 
Figure 4: Results of the one-way deterministic sensitivity analyses for each country – Tornado 
plots 
 
Figure 4A: cumulative budget impacts for Italy 
 
Figure 4B: cumulative budget impacts for Spain 
 
Figure 4C: cumulative budget impacts for Austria 
Hosp 0-1: hospitalization for 0-1 day (1 night) 
Hosp 2-3: hospitalization for 2-3 days (2-3 nights) 
ABSSSIs: Acute Bacterial Skin and Skin Structure Infections 






We identified 15,068 non-severe ABSSSI patients per year hospitalized in Italy, Spain and 
Austria through the administrative database of each country. The model assumed that the early 
administration of dalbavancin could accelerate the discharge of non-severe ABSSSI patients who 
currently spending 2 or 3 days in hospital settings. Patients could be discharged directly from the 
A&ED or their hospital LoS could be reduced. This new management approach could increase the 
quality of life of ABSSSI patients, who could be monitored at home, and reduce the overall costs 
from the NHS perspective by reducing the direct costs related to hospital management. 
The early use of dalbavancin reduced the hospitalization costs in the major part of the 
scenarios considered for each country; in Italy and Spain, these reductions generated a total 
expenditure savings for each year of the analysis. In Austria, the estimated cost reductions related 
to hospitalizations with a length of stay of 2-3 days generated savings only in the third year of the 
analysis. 
The outcomes of the model suggest that increasing the early use of dalbavancin could 
generate savings in the overall direct costs of management of non-severe ABSSSI patients from a 
NHS perspective. 
For ABSSSIs due to MRSA, the incremental length of hospitalization is the key cost driver [20]. 
New long-acting antibiotics represent a potential opportunity for early discharge not only for severe 
patients [17] but also for non-severe patients. This approach could modify the management of these 
infections with a considerable reduction in hospitalization costs [17, 21, 22]. Our findings were 
confirmed by a recent observational retrospective study in 29 hospitals in Spain; 15/69 (21.7%) 
patients were treated with dalbavancin for ABSSSIs, Staphylococcus aureus was identified as a major 
pathogen (11/15 patients), and 12/15 (80.0%) patients had a favourable clinical outcome (resolution 
of signs and symptoms related to bacterial infection) [23]. The use of dalbavancin was associated 
with an overall cost reduction and an estimated LoS reduction of 1160 days in their one-year analysis 
[23]. 
As in most economic models, this study has some limitations. First, due to the lack of country-
specific data, some transition probabilities and cost inputs were assumed to be the same as those 
estimated for the Italian scenario. These assumptions, however, were validated and discussed with 
key opinion leaders who agreed with the choice of inputs. 
Second, consulting a panel of experts was the only way to identify the advantages associated 




discharge rate of patients over the time period of the analysis was based on scenarios designated 
by the panel of clinical experts. Third, the probabilities of discharge with a successful clinical 
response, unlike the probabilities of discharge with a poor clinical response, for a LoS of 0-1 day 
were assumed to be the same as the probabilities estimated for a LoS of 2-3 days. The same 
assumption was made for the corresponding direct costs. 
Finally, the costs used were proxies derived from the DRG payments received. This might be 
one of the reasons why the use of dalbavancin in Austria was only cost-effective in the third year. 
As seen in Table 2, 2- to 3-day stays were approximately 5.5 times more expensive as 0- to 1-day 
stays in both Italy and Spain, but they were only 1.7 times more expensive as those in Austria. 
Therefore, despite the great potential to reduce long stays, especially in Austria, the cost-reducing 
effect is decreased. Adapting DRG weights similar to Italy and Spain would reflect the costs better, 
and the use of dalbavancin in Austria would probably then be associated with cost-savings in all 
years. 
The model was designed under a conservative assumption that the probabilities related to 
clinical response and clinical worsening were the same between the current standard of care and 
the dalbavancin scenarios. 
 
5. CONCLUSION 
The high economic burden of non-severe ABSSSIs is dependent on the length of stay (LOS) 
in the hospital [1, 23-25]. The characteristics of long-acting antibiotics could represent an 
opportunity for the targeted management of ABSSSIs. 
The decision-analytic model developed on the basis of the current clinical practices in three 
European countries suggested that increasing the early use of dalbavancin could significantly reduce 
both hospitalization rates and lengths of stay in non-severe ABSSSI patients. 
This new management approach could increase the quality of life of treated patients, who 
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Algorithm to identify ABSSSI patients in Italy (non-severe) 
The following algorithm was implemented for all acute inpatient admissions with discharge 
dates between January 1st, 2006, and December 31th, 2014, in the Italian Hospital Information 
System (HIS). 
To define non-severe patients requiring observation over 12 hours, one of the following 
inclusion criteria had to have been met: 
All acute inpatient admissions with discharge 
AND a primary diagnosis as follows: 
 “Cellulitis or abscess of the finger or toe” (ICD-9-CM 681.xx) 
 “Other cellulitis or abscess” (ICD-9-CM 682.x) 
 “Other local infection of the skin or subcutaneous tissue” (ICD-9-CM 686.xx) 
 “Posttraumatic wound infection not elsewhere classified” (ICD-9-CM 958.3) 
 “Other post-operative infection” (ICD-9-CM 998.59) 
OR 
• a diagnosis-related group (DRG) as follows: 
 “Cellulitis, age >17 with complications” (DRG 277) 
 “Cellulitis, age >17 without complications” (DRG 278) 
 “Post-operative or post-traumatic infection” (DRG 418) 
Exclusion criteria: 
 Hospitalized patients aged < 17 years 
 Hospitalizations with a length of stay < 1 day 
 
Definition of a “non-severe” case: 
All selected admissions with a length of stay ≤ 3 days 
AND a diagnosis-related group (DRG) not including the following: 
 “Subtotal mastectomy for malignancy with CC” (DRG 259) 
 “Extensive procedure unrelated to the principal diagnosis” (DRG 468) 
 “Ungroupable” (DRG 470) 
 “Prostatic procedure unrelated to the principal diagnosis” (DRG 476) 
 “Non-extensive procedure unrelated to the principal diagnosis” (DRG 477) 




 “Tracheostomy except for face, mouth and neck diagnoses” (DRG 483) 
 “Extracorporeal membrane oxygenation or tracheostomy with mechanical ventilation ≥ 96 hours or 
a principal diagnosis unrelated to the face, mouth and neck, with a major procedure” (DRG 541) 
 “Tracheostomy with mechanical ventilation ≥ 96 hours or a principal diagnosis unrelated to the face, 
mouth and neck, without a major procedure” (DRG 542) 
 
Algorithm to identify ABSSSI patients 
For mapping between ICD9-ICD10 codes, the “ICD-9 to ICD-10 Code Search | ICD-10 Code 
Lookup & Crosswalk” tool was used, and the correspondences  were double-checked. 
Algorithm to identify ABSSSI patients in Spain 
The Spanish official database 
(http://pestadistico.inteligenciadegestion.msssi.es/publicosns) was searched for -CIE-9  681, 682 




Algorithm to identify ABSSSI patients in Austria. 
In Austria, ABSSSIs are not as easily identified as in other countries. For example, many 
ABSSSIs, such as erysipelas, are coded as HDG19.07 “Komplizierte Affektionen der Haut”, a DRG 
group that also includes pemphigus vulgaris. A sub-group (HG156) is available but still includes 
diseases such as ulcus cruris and decubitus. We therefore requested all records for the ICD 10 codes 
from the Italian algorithm (using an ICD-9 to ICD-10 Code Search | ICD-10 Code Lookup & Crosswalk) 
together with their DRG codes from the Austrian Ministry of Health. Then, we identified plausible 
ICD/DRG combinations with the following algorithm: 
The DRG points of all acute-care stays of persons aged 20 years and over (the lowest category 
would have been 15-19) for the years 2008-20014 and the following: 
 LOS 0, 1, 2-3, 4+ (for each category) 
AND 
 An ICD10 equivalent of Italian algorithm ICD9 codes 
AND 
 HDG 19.07 
 HDG 19.08 




 MEL 06.05 
 MEL 09.03 






For each ICD10/DRG/LOS category, readmissions were also made available. Zero-day stays 
were not included in the cases but were requested for completeness. 
 
